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IMMUNE DEFENSE OF THE FEMALE LOWER REPRODUCTIVE TRACT AND 
THE USE OF MONOCLONAL ANTIBODY-BASED TOPICAL MICROBICIDE 
FILMS TO PROTECT AGAINST HIV INFECTION 
COREY J. COSTANZO 
ABSTRACT 
 Research on the human-immunodeficiency virus (HIV) and HIV 
transmission prevention methods is extensive, yet a female-controlled prevention 
method still does not exist. In many cultures where HIV prevalence is highest 
there are many social and cultural barriers to the prevention options currently 
available, specifically around the use of condoms. Topical microbicides could 
potentially offer a viable solution.   
 In heterosexually transmitted HIV, the epithelium of the lower female 
genital tract is the first place of contact with invading pathogens. A topical 
microbicide that could protect against infection across this barrier, without 
causing inflammation, would be an ideal product to protect women against 
infection. In previous studies, several microbicides were shown to cause 
inflammation and increase the risk of HIV infection; therefore, it is vitally 
important that any new topical microbicide products developed do not have the 
same effect. Our laboratory is collaborating with Mapp Biopharmaceuticals in the 
development of a new vaginal microbicide product based on human monoclonal 
antibodies produced in plants. Our prototype microbicide, MB66, is a film 
containing two antibodies: VRC01 (anti-HIV) and HSV-8 (anti HSV-2). We 
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hypothesize that the new MB66 topical microbicide film will provide protection 
against these sexually transmitted viruses without inducing inflammation in the 
vaginal epithelium, and will prove to be a viable topical microbicide product that 
does not cause inflammation and increase the risk of HIV infection. 
 MatTek vaginal epithelium models were used to test for any potential 
inflammation by the MB66 film. Active MB66 and placebo films were placed on 
the MatTek models. Vaginal tissue models grown in the presence of estradiol 
were also exposed to the active film. After being exposed to the active MB66 film, 
apical and basal supernatants were collected and analyzed for proinflammatory 
cytokines; IL-6, IL-8, MCP-1, and TNF-alpha. There were no significant increases 
in IL-6 or IL-8 expression in vaginal epithelium when exposed to the MB66 film. 
There was a significant decrease in the expression of TNF-alpha in the apical 
supernatant of the film-treated cultures at the 24 hour time point, and a very 
small (<1%) but statistically significant increase in the expression of MCP-1 in the 
basal supernatant of the film and the placebo after 24 hours. These results 
indicate that the active MB66 film did not induce a significant amount of 
inflammation in the vaginal epithelium.  
 Immunohistochemistry was used to ensure that the MatTek vaginal 
models are a valid representation of the native vaginal-ectocervical epithelium. 
Expression of toll-like receptors (TLRs) 2, 3, 4, 5, and 9 was compared in the 
MatTek models (partial and full thickness), as well as native vaginal and 
ectocervical tissue. Results show similar expression of all the TLR’s in the native 
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tissue and the partial and full thickness MatTek models. There was a greater 
degree of similarity between the native tissue and the full thickness MatTek 
models. Namely, there was a lack of expression with TLR 5 and TLR 9, and 
positive expression of TLRs 2, 4, and 9.  
 Overall, the TLR expression validated the use of these models in testing 
current and future topical microbicides in order to find an effective female-
controlled prevention method. In addition, cytokine analysis provided evidence 
that the new Mapp MB66 topical microbicide films do not cause significant 
inflammation to the vaginal-ectocervical tissue. Our data indicate that there 
should be further development of the MB66 film as a vaginal topical microbicide.  
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INTRODUCTION 
Human Immunodeficiency Virus Type 1 
The human immunodeficiency virus type 1 (HIV-1) is a human retrovirus that 
recently evolved from closely related simian immunodeficiency viruses endemic 
in wild ape populations in West Central Africa (Sharp, P. M., & Hahn, B. H., 
2011). The HIV-1 virion has a core that contains three components: capsid 
proteins, two copies of the viral transcriptome in the form of RNA, and three  
enzymes including reverse transcriptase, which synthesizes complementary DNA  
from viral RNA. In this way, the viral genome is incorporated into the host cell 
genome and successfully replicates. In addition to the core, the virus has an 
outer envelop which contains gp120 spikes, which enable the virus to infect 
target cells by interacting with the CD4 molecule present on the surface of CD4 T 
cells, macrophages and other cell types. CD4 molecules act as high affinity 
receptors for gp120, facilitating binding of the virus to the host cell. After HIV-1 
binds to the CD4 receptors on the surface of target cells, a conformational 
change occurs in gp120, exposing gp41 which binds to HIV co-receptors CCR5 
or CXCR4 leading to fusion of the viral envelop with the cell membrane allowing 
the virion to successfully insert its’ genetic components into the host cell (Huang, 
C., et al, 2007). HIV infection destroys the CD4 T cells in the body which leads to 
chronic inflammation resulting in an immunodeficiency state, termed the acquired 
immunodeficiency syndrome (AIDS). Since the start of the HIV/AIDS epidemic, 
over 78 million people have been infected with the virus and over 39 million 
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people have died.  Currently there are 35 million people living with HIV infection 
worldwide, with about 2.1 million new infections per year (UNAIDS, 2014).  Sub-
Saharan Africa is the hardest hit region with over 70% of the HIV/AIDS cases  
(UNAIDS, 2014). 
HIV Prevention Challenges  
When addressing HIV globally, social and cultural norms play a large part 
in why HIV continues to be spread. In many cultures, there are social factors that 
contribute to condom rejection and in turn the spread of HIV. Lack of dialogue 
between partners regarding condom use and also unequal power between 
partners when it comes to decisions regarding sexual health are two social 
factors that contribute greatly (Mash, 2010). Many women do not want condoms 
to reduce sexual pleasure for their partner, and the idea that condoms indicate a 
lack of trust and intimacy also deters use. Other social factors that contribute are 
religious beliefs that forbid the use of condoms and fear that using condoms will 
negatively affect a woman’s reputation (Mash, 2010). Even with more access to 
condoms and education about their use, these social and cultural norms and 
beliefs still persist and contribute to the spread of HIV. This is a major reason 
why a female-controlled, discreet, and accessible HIV prevention method is 
essential in curbing the spread of this virus.  
HIV Prevention Methods   
 Many HIV prevention strategies have been developed and tested. These 
strategies include condom use, abstinence, circumcision, drugs for pre-exposure 
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prophylaxis (PREP) or treatment as prevention, and topical microbicides. Multiple 
clinical trials, specifically ones conducted in Africa, have shown that circumcision 
is protective against HIV infection (Gray, R. H., et al, 2007). A randomized control 
trial conducted in Kisumu, Kenya showed that the protective effect of 
circumcision was 60% and suggests that wherever and whenever safely 
possible, voluntary circumcision services should be incorporated into HIV 
prevention interventions (Bailey, R. C., et al, 2007). Although circumcision has 
been shown to be effective, a major weakness of this service is the accessibility 
and expense of this service. In order to have this procedure, a patient must have 
access to health services that are able to conduct the procedure safely. This 
access is lacking in many locations, specifically sub-Saharan Africa, where HIV 
incidence rates are highest (White, R. G., et al, 2008). Abstinence and 
abstinence only programs are another HIV prevention method that have been 
explored. Although abstinence is completely effective in preventing sexually 
transmitted HIV infection, studies on abstinence only programs have shown that 
these types of programs do not impact delay in initiation of sexual intercourse, 
age at initiation of sex, number of sexual partners, or condom use; therefore, 
there is little hope that abstinence promotion would be effective at preventing the 
continued spread of HIV (Kirby, D. B., 2008).  
Condom use is a method of prevention that has proved very effective. A 
review of condom effectiveness in reducing heterosexual transmission concluded 
that proper condom use reduced HIV transmission by approximately 80% 
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(Weller, S., & Davis, K., 2002). In addition, low cost and high accessibility are 
major strengths of this prevention method. Unfortunately, as previously 
discussed, social norms and cultural values are often barriers of condom use in 
the developing world. Treatment as prevention is another method that has been 
researched and tested by providing patients at risk of infection with prophylaxis 
drugs containing two medications, Tenofovir and Emtricitabine, that prevent the 
virus from establishing infection (CDC, 2015). Although pre-exposure prophylaxis 
has shown to be effective in those with high adherence, barriers including cost, 
accessibility, awareness, and low adherence are significant weaknesses of this 
HIV prevention method (Krakower, D. S., & Mayer, K. H., 2015). 
In the past, topical microbicides have also been studied as a potential 
prevention method as they inactivate the pathogens that spread HIV. Specifically, 
Nonoxynol-9 is a microbicide that has been distributed and used widely for 
decades as a spermicide to kill sperm and potentially protect against the spread 
of HIV-1 virus (Fichorova, R. N., Tucker, L. D., & Anderson, D. J., 2001). 
Paradoxically, studies have shown that Nonoxynol-9 actually increases 
susceptibility to HIV and other sexually transmitted pathogens. A large-scale 
placebo controlled trial conducted with 892 female sex workers showed that 
vaginal gel containing Nonoxynol-9 did not protect against HIV and caused toxic 
effects that increased HIV infection (Van Damme, L., et al, 2002). In other 
studies, susceptibility to HIV increased with Nonoxynol-9 use because the 
microbicide increased inflammation in the vagina (Fichorova, R. N., Tucker, L. D., 
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& Anderson, D. J., 2001). Vaginal inflammation attracts easily infected HIV host 
cells to the genital tract epithelium and activates transcription of the virus in 
infected cells. This occurrence causes the vaginal epithelium to be substantially 
more vulnerable to the virus. Due to similar results from numerous studies, 
Nonoxynol-9 is no longer considered an HIV prevention option.  
Other nonspecific microbicide compounds have been developed for HIV 
prevention and tested in clinical trials. Compounds researched include Buffergel, 
Pro2000, Carragard, SAVVY vaginal gel, and cellulose sulphate. Results of these 
clinical trials provided evidence that none of these gels are significantly effective 
in preventing HIV infection (Abdool Karim, S. S., et al, 2011; McCormack, S., et 
al, 2010; Skoler-Karpoff, S., et al, 2008; Feldblum, P. J., et al, 2008; Van 
Damme, L., et al, 2008).  These results indicate that more research is needed in 
order to find alternative microbicides that would allow people, specifically women, 
to successfully protect themselves against HIV transmission. 
An additional class of microbicides being researched is topical microbicide 
gels containing antiretroviral medications that inhibit the viral reverse 
transcriptase enzyme. The reverse transcriptase enzyme converts viral RNA to 
DNA in an infected cell and is an essential component the virus needs to spread. 
One antiretroviral microbicide that has been studied is Tenofovir gel. The active 
antiretroviral component used in Tenofovir gel is 9-[(R)-2-phosphonomethoxy) 
propyl] adenine monohydrate (PMPA) (Karim, Q. A., et al, 2010). Tenofovir is a 
nucleotide reverse transcriptase inhibitor and was the first antiretroviral to be 
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tested in microbicides (Wilson, D. P., et al, 2008). Another antiretroviral being 
tested in microbicide gels is Dapivirine, which is a nonnucleoside reverse 
transcriptase inhibitor (NNRTI) (Wilson, D. P., et al, 2008). Tenofovir and 
Dapivirine are the two antiretroviral microbicides that have been tested most 
extensively.  
In the Caprisa clinical trials, results showed that Tenofovir gel reduced HIV 
infection by approximately 39% and women who used the gel consistently were 
up to 54 percent less likely to contract HIV (Karim, Q. A., et al, 2010).  In 
contrast, the results of the VOICE clinical trials, where Tenofovir tablets or 
Tenofovir gel were used, showed that neither of the products are effective in 
preventing HIV infection (Saag, M. S., 2015). In addition, results of the FACTS 
clinical trial, which tested the effectiveness of Tenofovir gel, showed that the gel 
showed a protective effect in women who used the gel consistently, but the 
adherence to the gel was too low to show the gel’s effectiveness (FACTS 001 
Results, 2015).  Overall, clinical trials of Tenofovir have had conflicted results, so 
more trials are needed to definitely determine the effectiveness of Tenofovir as 
an HIV prevention method.  
Topical Microbicides Containing Monoclonal Antibodies 
 Additional research is currently being completed with a goal of finding a 
female-controlled HIV protection method. One promising avenue of research is 
the use of plantibodies to protect against infection. Plantibodies are plant-made 
human monoclonal antibodies that are obtained from plants genetically altered to 
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express specific antibody genes and in turn produce specific antibodies (Jaeger, 
G. D. et al, 2000). Antibodies bind to specific antigens on pathogens resulting in 
neutralization and destruction of the pathogen by immune cells (Overbaugh, J., & 
Morris, L., 2012). Once the pathogen is detected by an antibody, other white 
blood cells are recruited, including neutrophils, macrophages, and dendritic cells. 
These cells are often able to phagocytose the pathogen and neutralize it with 
enzymes. These antibodies can be targeted against specific antigens or 
pathogens, including HIV (Overbaugh, J., & Morris, L.2012).  
 A cost effective way to manufacture human monoclonal antibodies is to 
produce them through genetic engineering in plants. By growing these types of 
plantibodies, cost is reduced greatly as compared to mammalian produced 
antibodies (Stoger et al, 2002). In addition, these antibodies can be applied 
topically and work in the localized region of the vagina to provide protection. 
Studies have shown that these types of plant-derived antibodies can function 
effectively for hours when exposed to the human vaginal environment (Stoger et 
al, 2002). Overall, this plantibody technology has shown to be effective in 
protecting against HIV transmission in mammals and is a promising step in 
finding an effective topical microbicide.  
 Two antibodies, VRCO1 and HSV-8-N have been studied in depth and are 
effective in targeting HIV-1 and HSV-2, respectively. The first, VRCO1, is a 
broadly neutralizing monoclonal antibody that is able to target multiple different 
strains of HIV (Su, B et al, 2014). VRCO1 binds to the CD4 binding site of the 
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specific envelope glycoprotein subunit, gp 120, found on the surface of cell free 
HIV-1 (Pantophlet, R., & Burton, D. R, 2006). This antibody was originally found 
and obtained from a patient infected with HIV and has been shown to be effective 
at protecting against HIV infection in both nonhuman primates and mice (Su. B, 
et al, 2014). The second antibody, HSV-8-N, is also a monoclonal antibody. This 
antibody is able to target HSV-2 (herpes simplex virus 2). HSV-8-N antibody 
functions by binding to the viral envelope glycoprotein D subunit located on the 
surface of the HSV virus and interfering with infection by neutralizing the virus 
(Whaley, K., Hume, S., & Zeitlin, L., 2014). Studies have shown that HSV-8-N is 
a potent neutralizer of HSV-2 and can target multiple strains of the virus (De 
Logu, A., et al, 1998). HSV-8-N is used in combination with VRCO1 as the HSV 
antibody protects against HSV infection, a major risk factor promoting HIV 
infection (CDC, 2010). Studies have shown that HSV-2 infection increases HIV 
acquisition by six-fold and that HSV-2 induced ulcerations create a breach in the 
genital epithelium allowing HIV virus to cross this physical barrier (Kaul, R., et al, 
2008). Overall, both of these antibodies, HSV-8-N and VRCO1, can be produced 
using plantibody technology making them extremely valuable in the search for a 
topical microbicide that will prevent the spread of HIV and HSV viruses.  
Innate Versus Adaptive Immunity Against HIV 
The immune system of the human body has two different components that 
work in conjunction to protect the body from pathogens, such as HIV. These two 
components are innate immunity and adaptive immunity. The adaptive response 
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is a longer-term response conducted against pathogens. It is delayed in onset 
and has highly specific receptors (Pudney, J., & Anderson, D., 2011).  Major 
contributors to the adaptive immune response are lymphocytes and products of 
lymphocytes, and an important difference in the adaptive immune system is the 
presence of immunologic memory that offers the body a form of long lasting 
protection. There are two different adaptive immune responses. Humoral 
immunity, which involves antibodies produced by B cells, and cellular immunity, 
which involves T cell lymphocytes (Pudney, J., & Anderson, D., 2011). The most 
distinguishing feature of the adaptive immune system is its’ highly specific 
response tailored to each specific pathogen (Alberts, 2002).  
In the female genital tract, the adaptive immune system mounts specific 
immune responses towards different bacterial, viral, and fungal pathogens, but it 
can take days for the adaptive immune system at the mucosal surfaces to be 
activated and effective against these pathogens (Wira, C. R., et al, 2005). 
Antibodies specific to each pathogen are generated during this time period. In 
order to produce these specific antibodies, the mucosal surface and epithelial 
cells of the female genital tract utilize antigen-presenting cells (APCs), a type of 
dendritic cell that reacts when a pathogen is present. APCs internalize the 
foreign antigen, break them down to immunogenic fragments, and present them 
to T cells using class I or class II major histocompatibility complex molecules 
(Wira, C. R., et al, 2005).  The activated cytotoxic T lymphocytes (CTLs) then 
travel around the body and when they encounter the same Class I molecule-
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antigen complexes, they release two enzymes, perforin and graunulysin, that 
cause the cell to lyse (Stenger, S., et al, 1998).  
B cell responses to the HIV-1 virus are different as they result in the 
development of antibodies against the virus. Once a matching antigen on a 
pathogen is detected, the B cells are triggered and T cells help them mature into 
plasma cells that produce antibodies against the specific antigen. Antibodies are 
then released into the blood and mark the cells that are infected for destruction 
and clearance by the liver and spleen. In the genital tract with HIV, this B cell 
response occurs for approximately one week and is followed by a phase where 
anti-gp1 antibodies circulate through the body. Anti-gp120 antibodies are also 
produced a few weeks later and target the V3 loop of gp120 on the HIV virion 
envelope (Overbaugh, J., & Morris, L., 2012). In addition, neutralization 
antibodies (NAbs) against the virus do appear, but not until months after the 
initial infection. Unfortunately, at this point in the infection there has been 
extensive spread of the virus and T cell counts are often extremely low.   
Innate Immunity 
The initial acting component of the human immune system is innate immunity. 
The innate immune response is the fast-acting immediate response that provides 
the body with a way to detect microbial pathogens promptly and control infection 
(Pudney, J., & Anderson, D., 2011). Cells that conduct this innate immune 
response are consistently synthesized and circulate throughout the body, 
providing a continuous defense against infection or pathogens. Major 
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contributors to this innate immune response include epithelial barriers of the skin, 
gastrointestinal tract, genital and respiratory tract (Kumar, V., Abbas, A., & Aster, 
J., 2013). In addition to physical barriers, various types of cells play a major part 
in the innate immune response. These cells include leukocytes (neutrophils and 
macrophages), natural killer cells, and various complement plasma proteins, 
which often have phagocytic, cytolytic, and antimicrobial properties that help 
provide immediate defense against pathogens (Woods, J. A., et al, 1999). An 
important feature of the innate immune system is its’ lack of specificity in 
targeting pathogens. The innate immune response is not specific to the particular 
pathogen, and this provides the body with a faster protection mechanism to 
defend against pathogens, as compared to the adaptive immune response.  
The innate immune system in the female genital tract provides protection 
against sexually transmitted pathogens. Firstly, the epithelial cells form a 
continuous mucosal barrier between the lumen and internal environment and 
external pathogens. Epithelial cells in the genital tract have the unique ability to 
provide a physical barrier against pathogens while also allowing the passage of 
sperm or ovum (Wira, C. R., et al, 2005). This physical barrier is composed of 
stratified squamous epithelium in the vagina and ectocervix, and tight junctions 
between columnar epithelial cells in the endocervix, endometrium, and fallopian 
tubes (Wira, C. R., et al, 2005). Epithelial cells in the female genital tract also 
contain toll like receptors (TLRs) that detect foreign pathogens and activate the 
innate immune system through molecular pathways that enhance the secretion of 
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inflammatory cytokines and interferons. In addition, microbicidal substances 
secreted from the epithelium help protect the female genital tract against 
pathogen infiltration. These microbicidal substances include soluble factors, such 
as defensin, secretory leukocyte peptidase inhibitor (SLPI), lysozyme and 
lactoferrin enzymes, and tracheal anti-microbial peptide (Wira, C. R., et al, 2005). 
Studies have shown that secretions by the epithelial cells in the female genital 
tract have a chemotactic effect that results in an increase of pro-inflammatory 
cytokines, such as IL-6, IL-8, MCP-1, and TNF-alpha, in the area (Wira, C. R., et 
al, 2005). As such, epithelial cells of the female genital tract are an essential 
component of the innate immune system in protecting the lower female 
reproductive tract against pathogens.  
Harnessing the Innate Immune System For HIV Prevention 
The innate immune system is especially important when looking at the spread 
of HIV and how to prevent infection. In the 1980’s and 1990’s, the majority of the 
research concerning HIV and the spread of this virus was focused on the 
adaptive immune system. After no successful vaccine was developed, there was 
a shift towards focusing on the innate immune system and developing a way to 
utilize the innate immune response to fight HIV-1 virus. When attempting to 
harness the innate immune response for HIV prevention, there are unique 
features of this system that require attention. Firstly, unlike the adaptive immune 
system that recognizes specific antigenic sequences, the innate immune system 
recognizes microbial features and patterns on the surface of the pathogen (Levy, 
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2001).  The ability to discriminate foreign pathogens from its’ own cells is a vital 
function of the immune system and is carried out by the innate immune system 
via pattern recognition receptors (PRRs) (Pudney, J., & Anderson, D., 2011). 
Pattern recognition receptors detect pathogen-associated molecular patterns 
(PAMPs) and can identify a variety of foreign pathogens attempting to infiltrate 
the body (Kumar, V., Abbas, A., & Aster, J., 2013). PRRs are found on the cell 
membrane and also inside the cytoplasm. One major advantage of PRRs is their 
ability to detect a variety of pathogens, including fungi, bacteria, viruses, and 
protozoa (Kumar, V., Abbas, A., & Aster, J., 2013). Their ability to identify and 
detect a range of pathogens is a valuable and unique feature of the innate 
immune system and is important in the body’s response to HIV.  
A second important feature of the innate immune system and its’ ability to 
defend against HIV is the anti-HIV soluble components that contribute to innate 
response. These components include mannose-binding lectins (MBLs) and 
complement (Levy, 2001). Mannose-binding lectin is a liver-derived serum 
protein that has the ability to bind and lyse HIV directly. Also, MBLs are able to 
differentiate the body’s normal cells from cells that are foreign, or the body’s own 
cells that have been transformed or altered; therefore, it can detect cells that 
have been infected by the virus (Takahashi, K., & Ezekowitz, R. A. B., 2005). 
Studies have shown that individuals with lower than normal levels of mannose-
binding lectin have an increased risk of HIV infection, and if they are infected with 
HIV there is rapid progression from infection to disease; therefore, mannose-
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binding lectin protein is an influential anti-HIV soluble component to consider 
when studying HIV infection (Levy, 2001). 
Another important anti-HIV soluble component of the innate immune system 
is complement. Complement is one of the many proteins in the complement 
cascade. The complement system is a major mediator of inflammation, and the 
system is composed of over 20 proteins that function in a cascade to induce 
inflammation when a pathogen is detected. In the innate immune response, when 
a pathogen is detected complement binds to the surface of the pathogen (Su, B. 
et al, 2014). When the first complement protein binds, there is a conformational 
change in the complex, which induces enzymatic activity leading to activation of 
the cascade and results in the lysis of the virus (Carroll, M. C., 2004). In addition, 
complement can act as an opsonin and trigger phagocytosis of the virus (Levy, 
2001).  
Another important component that allows the innate immune system to 
quickly and effectively protect against pathogens are antimicrobial peptides 
(AMPs). AMPs are small, cationic and amphipathic peptides that play a 
protective role in insects, invertebrates, and vertebrates (Reddy, K. V. R., 
Yedery, R. D., & Aranha, C., 2004). In humans, defensins were one of the first 
antimicrobial peptides to be discovered and studies have shown that defensin is 
secreted by the female genital tract epithelial cells in its’ innate immune defense. 
Specifically, human α-defensin-1, -2, and -3 coordinate anti-HIV actions in the 
female genital tract by contributing to the anti-HIV-1 activity of CD8 antiviral 
	   15	  
factor secreted by infected CD8 T cells (Reddy, K. V. R., Yedery, R. D., & 
Aranha, C., 2004). Other antimicrobial peptides such as cecropin and mellitin 
contribute by suppressing viral transcription, while polyphemusin prevents entry 
of HIV virus (Reddy, K. V. R., Yedery, R. D., & Aranha, C., 2004). 
Anti-HIV cellular components also function in the innate immune system to 
decrease the risk of infection or spread of the virus. The first of these cellular 
components are Interferon-producing cells (IPCs) and Type I Interferon (IFNs). 
Interferons block HIV replication and activate other components of the innate 
immune system, such as Natural Killer (NK) cells or macrophages, to help 
counter the virus (Levy, 2001). Another influential anti-HIV cellular component is 
CD8+ noncytotoxic T cell. Studies have shown that these cells control HIV 
replication in cells that have already been infected through the CD8+ T cell 
noncytotoxic antiviral (CNAR) response or by fragmenting the genetic material of 
the virus and digesting it using macrophages (Levy, 2001). Overall, interferons 
and CD8+ noncytotoxic T cells are two other important cellular components of 
the innate immune response against HIV. 
Inflammation and HIV Expression 
In addition to the soluble and cellular components that contribute to the 
defense system of the female genital tract, it is also important to note the role of 
inflammation in transmission of HIV, specifically in heterosexual transmission to 
women. Inflammation can occur when a pathogen infiltrates the mucosal 
surfaces or there is epithelial damage. When this occurs, the innate immune 
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system is activated via pattern recognition receptors. The pattern recognition 
receptors up regulate the transcription of genes that encode various 
proinflammatory cytokines. A few of the most common proinflammatory cytokines 
produced include Tumor Necrosis Factor (TNF-alpha), interleukin (IL-1, IL-6, IL-
8), and MCP-1. When these cytokines are synthesized, they are produced at the 
site of injury, and they recruit additional inflammatory cells to the area. The 
cytokines also function to regulate cell death, adjust vascular endothelial 
permeability, and recruit blood cells (Takeuchi, O., & Akira, S., 2010). Although, 
inflammation can help to repair injury to tissues, it has been found that in the 
female genital tract it actually makes the vaginal epithelium more prone to HIV 
infection. When inflammation occurs due to abrasion of the tissues or presence 
of sexually transmitted disease, the immune system is activated and 
inflammatory cytokines, specifically MCP-1, recruit CD4 cells to the site of tissue 
injury. Cells expressing CD4 are major HIV target cells and their presence 
increases HIV susceptibility (Deshmane, S. L. et al, 2009).  
Toll-Like Receptor Function 
The inflammatory response can be triggered by various toll-like receptors 
(TLRs). This major class of pattern-recognition receptors has an important 
function in detecting pathogens (Lancaster, G. et al, 2005). TLRs have been 
found to act as receptors for various types of ligands. These ligands include: 
bacteria, virus, fungi, and genomic DNA (Valanne, S., Wang, J.-H., & Rämet, M., 
2011). When a ligand reacts with a Toll like receptor, various signaling pathways 
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are activated, and different genes are expressed in an immune response. Two 
main signaling pathways are activated when the TLR reacts with its’ respective 
ligand (Chapel, H., & Haeney, M., 2014). The first signaling pathway activated is 
common to all toll-like receptors and is regulated by myeloid differentiation 
marker, MyD88. This pathway results in the activation of NF-κB, a transcription 
factor that regulates various genes that encode for proteins controlling 
inflammation. Once NF-κB is activated, it turns on transcription of these genes 
and as such acts as a master switch for inflammation within the body (Chapel, 
H., & Haeney, M., 2014). The second signaling pathway is not dependent on 
MyD88. Instead, when the toll-like receptors are activated by their respective 
ligands, the signaling cascade is regulated by TRIF. TRIF is an adaptor protein 
and activation leads to the secretion of Type 1 interferons, which as discussed 
have the ability to block HIV replication and activate other components of the 
innate immune system to help counter the virus (Chapel, H., & Haeney, M., 
2014). 
When pathogen ligands react with toll-like receptors in mammals, they 
trigger different pathways depending on the specific toll like receptor. There are 
10 different toll like receptors in the body, but for this study we chose to evaluate 
the expression of TLR2, TLR3, TLR4, TLR5, and TLR9.  Studies have shown 
that TLR2 mediates HIV-LTR trans-activation and HIV replication. Also, TLR9 
activation has also been shown to lead to HIV replication in transgenic mouse 
spleen cells.  
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 TLR2 responds to a variety of ligands, including yeast, lipoproteins, and 
Gram-positive bacteria. A unique feature of TLR2 is that dimerization of the TLR2 
cytoplasmic domain does not trigger cytokine production. On the contrary, when 
the cytoplasmic domain of TLR2 reacts with the domains of either TLR1 or TLR6, 
cytokine production does occur (Chapel, H., & Haeney, M., 2014).  
Unlike TLR2, the ligand that interacts with TLR3 is double stranded RNA 
(Bell, J. K. et al, 2005). Double stranded RNA is a distinct characteristic of 
viruses. The TLR3 receptors are usually located intracellularly in order to detect 
any viruses that infect the cell (Akira, S., Takeda, K., & Kaisho, T., 2001). 
TLR4 receptors interact and respond to lipopolysaccharides, which 
constitute an important part of the outer cell membranes of Gram-negative 
bacteria (Akira, S., Takeda, K., & Kaisho, T., 2001). Previous studies have shown 
that in the female reproductive tract, TLR4 expression is highest in the upper 
tissues including the fallopian tubes and the endometrium. The next highest 
expression of TLR4 is seen in the cervix followed by the ectocervix (Pioli, P. A., 
et al, 2004). On the contrary, in a different study TLR4 was expressed in the 
endocervix, endometrium, and uterine tubes, but was not present in the vagina 
and ectocervix (Fazeli, A., Bruce, C., & Anumba, D. O., 2005). In addition, TLR4 
in the human intestine has been shown to be decreased and prevent pro-
inflammatory responses against the body’s own bacteria in the gut (Pudney, J., & 
Anderson, D. J., 2011). 
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TLR5 is different than TLR4 as it recognizes and interacts with a bacterial 
component, flagellin. Flagellin is a protein present in the flagella of bacteria, 
which are finger-like projections located on the outer cell membrane of bacteria. 
Their primary function is locomotion as they help bacteria move and propel 
forward. TLR5 can identify flagellin in both Gram-positive and Gram-negative 
bacteria (Bell, J. K., et al, 2005). 
The ligand that TLR9 reacts with is unmethylated CpG DNA. 
Unmethylated CpG DNA has been shown to stimulate human lymphocytes 
(Witkin, S. S., Linhares, I. M., & Giraldo, P, 2007). It also has the ability to directly 
stimulate many immune cells including: B cells, macrophages, and dendritic 
cells. These immune cells then secrete cytokines, which are major contributors 
and regulators of the body’s immune response to HIV (Akira, S., Takeda, K., & 
Kaisho, T., 2001). 
Viral recognition by TLRs is mainly by TLR9 as it recognizes DNA and 
also by TLR3 that recognizes single and double stranded RNA (Mogensen, T. H., 
et al, 2010). Other pattern recognition receptors that recognize pathogen-
associated molecular patterns and contribute to the innate immune system 
include C-type lectin-like receptors (CLRs), NOD-like receptors (NLRs), and RIG-
like receptors (RLRs) (Takeuchi, O., & Akira, S., 2010). CLRs are a 
transmembrane protein, similar to TLRs, while NLRs and RLRs are located in the 
cytoplasm. Whenever these PRRs are activated by their ligands, they upregulate 
the transcription of genes that encode a variety of inflammatory components 
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including: proinflammatory cytokines, type I interferons, chemokines, and 
antimicrobial peptides (Takeuchi, O., & Akira, S., 2010). 
Figure 1. Toll-like receptors and their respective ligands. Toll like receptors 
all have specific ligands that they interact with. TLR2 with yeast, lipoproteins, and 
gram positive bacteria; TLR3 with double stranded DNA; TLR4 with 
lipopolysaccharides; TLR5 with bacterial flagellin; and TLR9 with CpG DNA.  
 
When TLR recognizes the foreign pattern of surface molecules on the 
pathogen various molecular pathways are activated. TLR 3 and 9 are expressed 
in the cytoplasm, while TLRs 2, 4, and 5 are expressed on the cell membrane, 
and whether the response is NF-kB dependent or independent depends on which 
TLR was activated. With TLR2, TLR3, and TLR4, this cascade of events leads to 
NF-kB separating from phosphorylated IkB and translocating to the nucleus 
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where it increase the transcription of genes encoding proinflammatory cytokines 
(Takeuchi, O., & Akira, S., 2010). The NF-kB independent pathway can also be 
activated by TLR4 and this cascade leads to IRF3 being phosphorylated and 
translocated into the nucleus, where it induces transcription of genes that 
produce proinflammatory cytokines and type I interferons. A similar molecular 
pathway is activated with TLR5 and NF-kB is translocated into the nucleus and 
upregulates the transcription of genes that code for proinflammatory cytokines. 
With TLR9, CpGDNA reacts with the TLR inside an endosome in the cytoplasm 
and leads to a MyD88 complex being recruited. The formation of this complex 
results in IRF7 translocating into the nucleus and upregulating the expression of 
type I interferon genes (Takeuchi, O., & Akira, S., 2010). 
 Some of the key cytokines that regulate inflammation include interleukin 6 
(IL-6), interleukin 8 (IL-8), monocyte chemo attractant protein 1 (MCP-1), and 
tumor necrosis factor alpha (TNF- α). These are some of the most common 
proinflammatory cytokines induced when infected with HIV virus, which is why 
they were chosen for this study. IL-6 plays an important role in the inflammatory 
response as it stimulates the activation of T cells, the differentiation of B cells, 
and production of acute phase proteins by the liver (Jones, S. A., et al, 2001). 
The function of IL-8 is to recruit neutrophils to the site of injury during the 
inflammatory response (Fichorova, R. N. et al, 2001). Studies have shown that 
both IL-6 and IL-8 promote the spread of HIV infection, as IL-6 induces HIV-1 
expression while IL-8 stimulates HIV-1 replication by recruiting susceptible cells 
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to the area of inflammation (Fichorova, R.N., et al, 2004). MCP-1 is another 
major chemo attractant during the inflammatory response that specifically recruits 
monocytes, memory T lymphocytes, and natural killer cells to the site of 
inflammation. Due to this recruitment, memory CD4+ T cells and monocytes are 
primary targets for HIV infection, and this contributes greatly to these types of 
cells spreading the virus (Deshmane, S. L. et al, 2009). TNF-α is also an 
inflammatory cytokine produced by macrophages and monocytes during the 
acute inflammatory response. TNF-α has many diverse functions and roles in the 
body and in the immune system as it activates neutrophils and platelets, 
enhances the killing abilities of macrophages and natural killer cells, and also 
mediates apoptosis by activating caspases that cleave proteins. In addition, TNF-
α is able to alter the anion and cation channels of the cell membrane and in turn 
affect the cell volume, which can result in necrosis or apoptosis of the cell (Idriss, 
H. T., & Naismith, J. H., 2000).  Specifically with HIV-1, studies have shown that 
TNF-alpha can increase epithelial tight junction permeability and increase the risk 
of HIV infection across the genital epithelial barrier (Nazli, A., et al, 2010).  
Genital Mucosal Barrier 
To date the most common paths of becoming infected with HIV are 
through sexual transmission or injection drug use (Shen, R., Richter, H. E., & 
Smith, P. D., 2014). Heterosexual contacts constitute approximately 34% of HIV 
infections (Kumar, V., Abbas, A., & Aster, J., 2013). In addition, women account 
for approximately 52% of HIV-1 infections (Women and HIV/AIDS, 2012). The 
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frequency of heterosexual transmission makes the genital mucosal barrier a 
particularly important aspect to consider when researching HIV-1 and sexually 
transmitted infections. For women, the site of primary heterosexual HIV-1 
infection is the vaginal epithelium, and it is the first point of contact between 
sexually transmitted pathogens and the mucosal surface (Anderson, D. J., 
Marathe, J., & Pudney, J., 2014). The epithelium of the vaginal wall has different 
layers. The outermost layer of the epithelium is the vaginal stratum corneum, and 
it is a permeable layer composed of non-keratinizing stratified squamous cells 
(Anderson, D. J., Marathe, J., & Pudney, J., 2014). In this layer there exists an 
abundance of antimicrobial peptides and glycogen. This superficial layer is made 
up of flattened cells that have experienced cornification, a terminal cell 
differentiation where the nucleus and intercellular organelles are lost and DNA 
and RNA are broken down, inhibiting further production of new proteins. This 
cornification process is influential as it causes intercellular junctions to act less 
effectively and diminishes the ability of the epithelial cells to respond to microbial 
exposure (Anderson, D. J., Marathe, J., & Pudney, J., 2014) 
HIV Transmission Mechanisms 
 There are multiple transmission routes to acquire the HIV virus. The 
heterosexual route of transmission is the most common transmission route 
worldwide. Mother to child, or vertical, transmission of HIV-1 can occur during 
birth or after birth of the child. The virus can be transmitted from mother to child 
during pregnancy, labor, delivery, or breast feeding. Another route to acquire HIV 
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is through needles or syringes, often associated with injection drug use. Lastly, 
blood transfusion or transfusion of blood products can spread the virus as well 
(CDC, 2014). These different transmission routes have different rates of HIV 
infection, and although heterosexual routes of transmission are the most 
common transmission routes, this route has the lowest infection rates with 
heterosexual activity resulting in HIV infection in only 1 per 1,500 sexual 
encounters. Vertical transmission has a much higher infection rate with 1 out of 
every 3 babies born to a mother with HIV being infected with the virus (Pier, G. 
B., Lyczak, J. B., & Wetzler, L. M., 2004).  
 When searching for a female-controlled HIV prevention method, 
heterosexual transmission is the most important route to research. Heterosexual 
transmission has been seen to occur rapidly within 30 to 60 minutes of initial 
exposure when HIV virus crosses the epithelial barrier of the female genital tract. 
Ex-vivo studies have also shown that both cell-free and cell-associated HIV-1 
transmission can occur and that HIV infection can occur solely through invasion 
of the vaginal mucosa (Hladik, F., & McElrath, M. J., 2008). Cell free 
transmission occurs when HIV virions from infected seminal cells interact with the 
genital tract epithelial cells and cross the epithelium through transcytosis, 
endocytosis, subsequent exocytosis, or by moving through the spaces in 
between the epithelial cells (Hladik, F., & McElrath, M. J., 2008).  
Some studies have also shown that HIV-1 virions can bind to and enter 
epithelial cells, be sequestered in endocytic compartments or cytosol, and then 
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be released and infect susceptible leukocytes. These results show that these 
cell-associated HIV virions are often more effective at transcytosing the epithelial 
barrier, as compared to cell-free virions. In addition, as suggested in mouse 
studies, HIV-1 can potentially infect by being transported by lymphocytes and 
macrophages through cervicovaginal epithelium  (Hladik, F., & McElrath, M. J., 
2008). The results of ex-vivo studies conducted in sheets of vaginal epithelium 
show that HIV-virions are located specifically in the basal and suprabasal 
epithelial cells, suggesting that HIV-1 most likely dispersed through the spaces 
between the epithelial cells versus entering and transversing through them. With 
this route, HIV virions can directly contact the susceptible Langerhans cells (LCs) 
and CD4+ T cells underneath (Figure 2). Cells located in the suprabasal or basal 
epithelium of the female genital tract often have distinguishng characteristcs that 
cause them to be more prone to sequestering and trancytosing HIV-1 virus. 
Langerhans cells have a unique ability to extend their dendrites up through the 
epithelial spaces towards the surface of the epithelium and bind HIV (Hladik, F., 
& McElrath, M. J., 2008). Studies have shown that Langerhans cells can even 
take up HIV-1 virions into their cytoplasm and then exit the genital epithelium to 
transport the virus to different locations, effectively spreading the virus (Hladik, 
F., & McElrath, M. J., 2008). Interestingly, human explant studies have shown 
that HIV-1 is extremely efficient at targeting CD4+ T cells in the genital tract for 
infection and that initial infection predominantly occurs in CD4+ T cells, versus 
Langerhans cells (Hladik, F., & McElrath, M. J., 2008).  
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 Cell surface components of the epithelial cells in the female genital tract 
are also very influential in the transmission of HIV-1. Surface proteins located on 
epithelial cells may support the attachment of HIV-1 and glycosphingolipids, such 
as lactosylceramide and galactosylceramide, have the ability to bind the gp120 
on the HIV-1 viral envelope and induce transcytosis of HIV virions in the epithelial 
cell (Hladik, F., & McElrath, M. J., 2008). Recent studies have also shown that 
another glycoprotein, gp340, located on genital epithelial cells binds to the HIV 
viral envelope protein and fosters the movement of HIV through the epithelial 
barrier to the susceptible leukocytes in the basal layer (Stoddard, E., et al, 2007).  
In addition to the characteristics of the epithelial barrier that affect 
infection, inflammation is a major risk factor in HIV transmission. Inflammation 
can occur due to epithelial tissue damage and cause a breach in the epithelial 
barrier. HIV virions can then cross the epithelial barrier with more ease and infect 
the inflammatory cells, such as CD4 cells, that are responding to the tissue 
injury. Specifically, small lesions of the mucosal epithelium caused by sexual 
intercourse can provide HIV-1 virions with direct access to the underlying 
dendritic cells, T cells, and macrophages that are easily infected (Figure 2). 
Certain topical microbicides or sexually transmitted infections can also cause 
these types of abrasions leading to increased HIV-1 susceptibility (Hladik, F., & 
McElrath, M. J., 2008). 
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Figure 2. HIV transmission across epithelial barrier. HIV virions 
are easily able to access susceptible dendritic cells (a), macrophages (b), 
and T cells (c) when physical abrasions or lesions result from sexual 
intercourse. Langerhans cells are able to reach up through the epithelial 
barrier and provide access to HIV virions as well. (Figure from Shattock, 
R. J., & Moore, J. P., 2003).  
 
Goals of Current Research  
 The current research seeks to evaluate the safety of MB66 microbicide 
film through cytokine analysis and TLR expression analysis. As seen through 
past studies, many topical microbicides have been shown to induce inflammation 
and in turn increase HIV susceptibility; therefore, it is imperative to ensure that 
this effect is not seen with the new MB66 microbicide film before testing the film 
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in human trials. By researching a new topical microbicide we are contributing to 
the efforts of creating a female-controlled HIV prevention method to curb the 
spread of sexually transmitted HIV infection.  
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SPECIFIC AIMS AND OBJECTIVES 
Up until recently HIV prevention has been mainly focused on the use of 
condoms or trying to generate an HIV vaccine. The development of vaginal films 
containing microbicide could potentially provide a way for women to protect 
themselves against HIV transmission and other sexually transmitted infections, 
without the use of a condom. It is important to determine any adverse effects 
these films could potentially have before testing them in large scale human 
clinical trials; therefore, the goal of the present research is to test if any markers 
of inflammation are produced by these films on MatTek vaginal-ectocervical 
models. If a severe reaction is observed, this could potentially have a similar 
effect on vaginal-ectocervical tissue in women. Also, it is important to determine if 
the safety of the MB66 microbicidal film is affected in any way when exposed to 
high levels of estradiol. In addition, it is important to validate the use of the 
MatTek models in testing new topical microbicidal products and ensure that there 
is a similar immune response in both native tissue and the MatTek partial and full 
thickness vaginal-ectocervical tissue models. Specifically, the aims of this 
research were: 
1) Determine IL-6, IL-8, MCP-1, and TNF-alpha cytokine expression 
changes in vaginal-ectocervical tissue epithelium when utilizing the MB66 
and placebo films on MatTek models 
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2) Determine IL-6, IL-8, MCP-1, and TNF-alpha cytokine expression 
changes in vaginal-ectocervical tissue when utilizing MB66 and placebo 
film in tissue is grown in the presence of estradiol  
3) Compare expression of TLR2, TLR3, TLR4, TLR5, and TLR9 by native 
vaginal and ectocervical tissue with partial and full thickness MatTek 
vaginal-ectocervical tissue models 
From these studies, I hope to learn if the MB66 microbicidal films cause 
any inflammation in the vaginal/ectocervical tissue. Also, I hope to validate the 
use of MatTek models for microbicide screening and discover any differences in 
TLR expression between the partial versus full thickness MatTek models and the 
native vaginal and ectocervical tissue.  
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METHODS 
TLR Expression Experiment  
 Tissues 
 The tissues used for this research were obtained from human subjects; 
therefore, this research has been approved by the Institutional Review Boards of 
Boston University. The female reproductive tissues were obtained as discarded 
surgical specimens. They originated either from samples of the vaginal mucosa 
from women undergoing a vaginal repair procedure or ectocervical tissues from 
women undergoing a hysterectomy. Nine samples from three different women 
were obtained from women undergoing vaginal repair and five samples of the 
ectocervix from four different women undergoing a hysterectomy. The ectocervix 
is contiguous with the vaginal vault and histologically the epithelium is the same 
as that for the vaginal mucosa. The surgical tissue samples obtained were coded 
and patient identifiers were eliminated from all laboratory records to ensure 
patient confidentiality. 
The MatTek tissue model is a three-dimensional organotypical vaginal-
ectocervical model produced by the MatTek Corportation, located in Ashland, 
Massachusetts. They are made from human-derived vaginal-ectocervical 
epithelial cells. These tissue models were used in the cytokine analysis and the 
TLR expression experiments. For the TLR expression experiment, there were 
five MatTek organotypic vaginal/ectocervical partial thickness samples and five 
full thickness model samples. The partial thickness tissue is composed of only 
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epithelium, while the full thickness model is made up of the epithelium resting on 
a lamina propria derived from autologous fibroblasts. All tissue specimens were 
fixed in 10% unbuffered methanol-free formaldehyde and processed for 
embedding in wax.  
Immunohistochemistry 
 5-µm-thick sections of tissue samples were collected on glass slides, de-
waxed, and rehydrated in a graded series of ethanols. An antigen retrieval 
protocol was used to unmask reactive epitopes. The sections were immersed in 
citrate buffer pH6 and placed in pressure cooker which was then heated to a 
temperature of 125°C for 30 seconds. The slides were then cooled for ten 
minutes after which they were washed several times with distilled water and 
placed in Tris-buffered saline containing 0.1% Tween 20 (TBST).  
 Sections were incubated for 30 minutes with a serum-free protein blocking 
solution (Dako, Carpinteria, CA, USA), to block any non-specific binding of 
antibodies, and then drained from the tissue sections prior to the application of 
primary antibodies. Antibodies specific for TLRs 2, 4, and 9 were obtained from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and the TLR 2 and 5 
were supplied by Novus Biologicals, Littleton, CO, USA.  
 Rabbit or mouse primary antibodies were diluted in a proprietary antibody 
diluent (Dako) at the following concentrations: TLR2 1:90, TLR3 1:90, TLR4 1;80, 
TLR5 1:80, and TLR9 1:100. Tissue sections were incubated with the primary 
antibody for one hour at room temperature and then washed twice in TBST for 
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five minutes each. Primary antibodies were detected using proprietary secondary 
reagents (MACH4 Universal AP Polymer Kit Biocare, Concord, CA, USA).  This 
system detects both mouse and rabbit primary antibodies. For mouse antibodies 
(TLR2 and 4) the sections were incubated with the MACH4 Universal AP Probe 
for 15 minutes. The sections were then washed twice in TBST for 5 minutes and 
then incubated with the MACH4 MR AP Polymer for a further 15 minutes. Finally 
the sections were washed twice in TBST buffer. For the rabbit antibodies (TLR3, 
5 and 9) the sections were only incubated with the MACH4 universal AP Probe 
for 30 minutes. They were then washed twice in TBST buffer. The antibodies 
were visualized by incubating the sections with a substrate for alkaline 
phosphatase (Fast Red Dako) that stains positive cells and tissues a bright red. 
Development of the staining was monitored under a light microscope. After a final 
wash, the sections were counterstained in aqueous hematoxylin, mounted in a 
glycerin-based mounting medium and cover slipped. For negative controls that 
act as a check of non-specific binding of antibodies, primary antibodies  were 
replaced by the antibody diluent only. The tissue sections were then treated 
exactly as those exposed to the primary antibodies.  
Protein Cytokine Analysis MB66 Film Experiment 
Two experiments were completed in order to evaluate the effect of Mab films 
on vaginal tissue. In the first experiment, placebo film and active film (MB66) with 
antibodies were added to MatTek vaginal-ectocervical tissue models and 
compared to the control. These films were manufactured by Kentucky 
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Bioprocessing, LLC and are meant to protect against the transmission of HIV-1 
and herpes simplex virus (HSV-2). The antibodies used on the films were formed 
using plantibody technology. The active film is composed of polyvinyl alcohol 
(60%), maltitol (25%), histidine (0.1%), polysorbate 20 (0.01%), water (5%), 
HSV8-N monoclonal antibody (5%), and VRCO1-N monoclonal antibody (5%).  
The MB66 film contains 10 mg of VRCO1-N and 10 mg of HSV8-N. This film is 2 
inches by 2 inches, with a thickness of 0.06 mm and a mass of 0.2 grams. The 
placebo film includes all of the same components as the active film, except for 
the HSV8-N and VRCO1-N monoclonal antibodies. Before being added to the 
tissues, a quarter of the film was dissolved in 1 mL of medium and 100 µL were 
placed on top of MatTek models. A Bio-Plex Pro Human Cytokine 4-plex Assay 
was used to determine if the films triggered immune response or inflammation 
among the cells in the vaginal epithelial model. This kit was used to detect four 
different human cytokines; IL-6, IL-8, MCP-1, and TNF-α. The tissues were then 
incubated at 37 degrees Celsius for four or twenty-four hours, and then 
harvested for basal and apical supernatants. The basal and apical supernatants 
were then tested for expression of the various cytokines.  
In the second experiment, the films were added to the MatTek tissue models 
that were exposed to different environmental growth conditions. The tissues were 
grown in the presence of either basal medium or basal medium with 100 nM 
estradiol (E2) in order to mimic menstrual cycle peak. In addition, either active 
MB66 film or no film was placed directly onto the different vaginal tissue models 
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and incubated at 37 degrees Celsius for 24 hours. In this case, the models 
without the film acted as the control. The basal supernatants were then 
harvested, since here the surface of the tissue was at the air interface, and 
tested for any expression of cytokines IL-6, IL-8, MCP-1, and TNF-alpha.  
Statistical Methods 
 In experiment 1, log transformed data were analyzed by Kruskal-Wallis 
non-parametric analysis of variance (ANOVA).  Significant (p<0.05) Kruskal-
Wallis tests were followed by Fisher’s PLSD post-hoc tests for pairwise 
comparisons. No statistics were conducted for experiment two as only singleton 
or duplicate samples were obtained.  
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RESULTS 
 
Cytokine Analysis Results 
 Experiment 1  
 The first cytokine analysis experiment added microbicide Mapp MB66 film 
to the vaginal tissue models to see if it induces inflammation. As seen in figures 3 
and 4, there were no significant differences seen in IL-6 and IL-8 cytokine 
expression between the control, placebo, and MB66 film exposed tissue at 4 or 
24 hours.  
 
Figure 3. IL-6 expression in basal and apical supernatants at 4 and 24 
hours in control, placebo film, and MB66 film exposed MatTek tissue 
models. Results show greater expression of IL-6 in basal supernatants as 
compared to apical supernatants in all models, yet the differences between the 
conditions (control, placebo, or MB66 film) were not statistically significant at 
either time point. 
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Figure 4. IL-8 expression in basal and apical supernatants at 4 and 24 
hours in control, placebo film, and MB66 film exposed MatTek tissue 
models. Results show greater expression of IL-8 in apical supernatants as 
compared to basal supernatants in all models, yet the differences between the 
conditions (control, placebo, or MB66 film) were not significantly different at 
either time point.  
 
 In figure 5, the expression of TNF-alpha in the apical supernatant of the 
control after 24 hours was significantly greater than the expression in both the 
placebo and MB66 film at the same time point (both p<0.05). Less TNF-alpha 
expression suggests that a decrease in inflammation could be a positive side 
effect of the MB66 and placebo films. As seen in figure 6, the expression of 
MCP-1 in the basal supernatant after 24 hours was significantly greater in both 
the MB66 film and the placebo, as compared to the control (p<0.001).  However, 
although the results are statistically significant (Figure 6), the difference in MCP-1 
expression between the control, placebo, and MB66 film is quite small in 
magnitude.  
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Figure 5. TNF-alpha expression in basal and apical supernatants at 4 and 
24 hours in control, placebo film, and MB66 film exposed MatTek tissue 
models. Results show greater expression of TNF-alpha in apical supernatants 
as compared to basal supernatants in the control and placebo models at the 4 
hour time point. At the 24 hour time point, the expression of TNF-alpha was 
significantly reduced (p<0.05) in the apical supernatants of the placebo and the 
film. 
 
Figure 6. MCP-1 expression in basal and apical supernatants at 4 and 24 
hours in control, placebo film, and MB66 film exposed MaTek tissue 
models. Results show the expression of MCP-1 in the basal supernatant at the 
24 hour time point was significantly greater (p<0.001) in both the film and the 
placebo as compared to the control.  
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Experiment 2 
 In the second experiment, the film was placed on top of the MatTek 
vaginal tissue grown in estradiol and compared to the control grown in medium. 
Only basal supernatants were analyzed, as the film was not dissolved in this 
experiment. In addition, duplicate or singleton samples were analyzed so no 
statistics were completed, although trends in the results were observed. In figure 
7, there was an increase in the expression of IL-6 cytokine in the estradiol growth 
condition as compared to the control. There was a 1.8 fold increase in expression 
of IL-6 on the tissue exposed to estradiol and microbicide film, as compared to 
the control tissue exposed to estradiol and no film.  
 
Figure 7. IL-6 expression in basal supernatant of tissue exposed to medium 
or estradiol. Results show that when the film was added to the MatTek tissue 
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model, there was an increase in the expression of IL-6. The model exposed to 
estradiol and film showed a greater increase in IL-6, as compared to its’ media 
control.  
 
 
 In figure 8, the results do not show a great difference in the expression of 
IL-8 between the control and the MB66 film exposed tissue with the medium 
exposed tissue models. Under the estradiol growth condition, the expression of 
IL-8 in the tissue model increased the most when exposed to the microbicide 
film. A 1.7 fold increase in IL-8 was seen when the estradiol model was exposed 
to the film.  
 
 
Figure 8. IL-8 expression in basal supernatant of tissue exposed to medium 
or estradiol. The results show that there was not a large difference in the 
expression of IL-8 between the controls and the film exposed tissue in the 
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medium model. There was a 1.7 fold increase in IL-8 in the estradiol model 
exposed to film, as compared to the estradiol control.  
 
In figure 9, the results do not show a great difference in MCP-1 between the 
control and the MB66 film exposed tissues under the different growth conditions. 
A unique result seen is the slight decrease in MCP-1 when exposed to film, as 
compared to the control model exposed to only medium and no film. Although 
this change was very small, it was the only result that showed a decrease when 
MB66 film was added to the tissue model. In contrast, with the estradiol model, 
there was a slight increase in MCP-1 expression when film was added, as 
compared to the estradiol model with no film.  
 
Figure 9. MCP-1 expression in basal supernatant of tissue exposed to 
medium or estradiol. Results do not show a great difference in the expression 
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of MCP-1 in the MB66 film exposed tissue compared to the control under any of 
the growth conditions. There is a slight decrease in expression of MCP-1 with the 
film when exposed in the model grown in medium, as compared to the control 
with no film.   
 
In figure 10, the results show that overall expression levels of TNF-alpha are very 
small compared to the other cytokines. There is hardly any expression of TNF-
alpha in both the control and the MB66 film exposed models when grown with 
medium. A two-fold increase in expression of TNF-alpha in the MB66 film 
exposed tissue, as compared to the control, was seen with the models grown in 
the presence of estradiol.   
 
Figure 10. TNF-alpha expression in basal supernatant of tissue exposed to 
medium or estradiol. Results show the least amounts of TNF-alpha expression 
under all growth conditions, as compared to the other cytokines analyzed. There 
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was almost no expression of TNF-alpha in the control and the film exposed 
tissues, with the tissue models grown in medium. A two fold increase in TNF-
alpha expression was seen in the film exposed estradiol model, as compared to 
the estradiol control with no film.  
  
Detection of TLRs in Vaginal Tissue by Immunohistochemistry 
 Immunohistochemistry was used to evaluate and compare TLR 
expression on the partial and full thickness MatTek tissue models, as compared 
to the native vaginal and ectocervical tissue samples. A bright red signal 
indicated positive staining for the specific toll like receptor.   
TLR 2 
A.      B. 
     
C.  
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Figure 11. TLR 2 expression in native tissue as compared to partial and full 
thickness MatTek tissue models. Immunohistochemistry showed that TLR 2 
expression was present in the epithelium of all native tissue samples. All of the 
MatTek tissue samples also stained positive for TLR 2. Panel A shows the native 
tissue, panel B shows the partial thickness MatTek model, and panel C shows 
the full thickness MatTek model. 
  
The epithelium of all samples of the vaginal and ectocervical mucosa 
stained positive for TLR 2. This expression of TLR 2 was mostly present in basal 
layer of epithelial cells, as seen in Figure 11A. For a few of the tissues, staining 
for TLR 2 was localized along the length of the epithelium but for the majority of 
the epithelium tissue in the section, TLR 2 expression was seen. Blood vessels 
and cells, most likely white blood cells, were present in the lamina propria and 
also stained intensely positive for TLR 2. 
All the MatTek tissue samples analyzed also stained positive for TLR 2. 
Similar to the native vaginal mucosa, the expression of TLR 2 by the partial 
thickness model was restricted to the basal layer of epithelial cells, as witnessed 
in Figure 11B. However, in the full thickness tissues, the expression of TLR2 was 
detected in several layers of the basal epithelium, as shown in Figure 11C. 
Fibroblasts present in the lamina propria like tissue of the full thickness model 
also stained intensely positive for TLR 2. 
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TLR 3  
A.      B. 
     
Figure 12. TLR 3 expression in native tissue as compared to partial 
thickness MatTek tissue models. Immunohistochemistry showed that the 
majority of the native vaginal and ectocervical tissue samples, as seen in panel 
A, did not show much TLR 3 expression. Panel B, also showed that there was 
limited expression of TLR 3 in the MatTek vaginal tissue models as well.   
 
The epithelium of all the samples of vaginal and ectocervical tissue, 
except one section, stained negative for TLR 3. Although, as seen in Figure 12A, 
the one positive tissue sample had only a small localized portion of the basal 
layer of epithelial cells that expressed TLR 3. Blood vessels and cells in the 
lamina propria were only found to stain weakly positive for TLR 3. Similar to the 
vaginal mucosa, the epithelium and fibroblasts of all of the full thickness tissue 
models stained negative or showed very weak positive staining for the 
expression of TLR 3. In contrast, it was observed that the basal layer of the 
epithelium of the partial thickness MatTek model stained intensely positive for 
TLR 3, as seen in Figure 12B.  
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TLR 4 
A.      B. 
     
   C. 
 
Figure 13. TLR 4 expression in native tissue as compared to partial and full 
thickness MatTek tissue models. Immunohistochemistry showed that the 
majority of the native tissue samples stained positive for TLR 4 expression, as 
seen in panel A. Also, as seen in panel B, all the samples of the MatTek full 
thickness model stained positive for TLR 4. 
 
The epithelium of 11 out of the 14 native samples stained positive for TLR 
4. This group was composed of 5 vaginal samples and 6 ectocervical samples. 
This expression of TLR 4 was detected primarily on the basal layer of epithelial 
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cells and was very extensive. As seen in Figure 13A, the staining often occurred 
along the entire length of the epithelium that was present in the tissue section. 
Blood vessels and cells in the lamina propria also often stained intensely positive 
for TLR 4. 
In addition, all the samples of the MatTek full thickness model stained 
positive for TLR 4. As seen in Figure 13B, this expression was seen in the basal 
layers of the epithelium. Also, the fibroblasts present in the lamina propria like 
tissue stained intensely positive for TLR 4. One unique result was that no specific 
staining for TLR 4 was detected in the epithelium of any of the MatTek partial 
thickness tissue models. This was in contrast to the strong positive staining of the 
full thickness models.  
TLR 5 
 When staining for TLR 5, no specific positive staining was detected in the 
epithelium of any of the vaginal or ectocervical tissue samples. Also, there was 
none or extremely weak positive staining of blood vessels or cells in the lamina 
propria. In addition, there was no expression of TLR 5 in the epithelium of either 
the full or partial thickness MatTek tissue models. Fibroblasts that were present 
in the lamina propria like tissue of the full thickness model also did not stain 
positive for TLR 5. 
 
 
 
	   48	  
 
TLR 9  
A.      B.  
    
C. 
 
Figure 14. TLR 9 expression in native tissue as compared to MatTek tissue 
models. Immunohistochemistry showed positive staining and expression of TLR 
9 in the native vaginal and ectocervical tissue samples, as seen in panel A. 
Similarly, in panel B, the MatTek full thickness models stained positive for TLR 9 
as well. In addition, the MatTek partial thickness models showed many cells 
staining positive for TLR 9.  
 
TLR 9 positive staining was seen in epithelial cells in all vaginal and 
ectocervical mucosa samples. Although, the amount of positive staining was 
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quite variable. The amount positive cells ranged from very few to extremely 
numerous in the different samples. As can be seen in Figure 14A, the cells that 
did stain positive were scattered within the supra-basal and apical layers along 
the entire length of the epithelium. In addition, there was no expression of TLR 9 
seen in either the basal epithelial cells or by blood vessels and cells in the lamina 
propria.  
Similar to the vaginal mucosa, TLR 9 positive epithelial cells were present 
in varying numbers in the suprabasal layers of the epithelium of the MatTek full 
thickness vaginal-ectocervical tissue model. This staining can be seen in Figure 
14B. In addition, no positive staining for TLR 9 was detected for fibroblasts in the 
lamina propria like tissue of the full thickness tissue model. Finally, as seen in 
Figure 14C, numerous TLR 9 positive epithelial cells were detected in the partial 
thickness model.   
Negative Controls 
A.      B. 
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C. 
 
Figure 15. Negative controls for immunohistochemistry. This picture shows 
the negative controls for the native vaginal epithelium (panel A), the full thickness 
MatTek vaginal-ectocervical model (panel B), and the partial thickness MatTek 
vaginal-ectocervical model. Little to no background or non-specific staining was 
found on the negative controls. 
 
 There was no or very little background or non-specific staining that could 
be detected on the negative controls of the vaginal mucosa (Figure 15A) or either 
of the two MatTek models (Figure 15B and 15C).  
 
 
 
 
 
 
 
 
 
 
	   51	  
DISCUSSION 
 Inflammation in the vaginal epithelium can cause more susceptibility and 
increase the risk of infection by HIV by depleting this physical barrier and 
recruiting more HIV susceptible cells to the site of tissue injury. Previous studies  
have shown that topical microbicides can induce inflammation in the vaginal 
epithelium and cause higher rates of HIV transmission. For my thesis research, I 
set out to prove that the new MB66 topical microbicide film produced by Mapp 
Pharmaceuticals, does not induce inflammation in the vaginal epithelium and is 
therefore a viable topical microbicide that could potentially be used and 
distributed as a safe female-controlled HIV prevention method. This subtle 
prevention method dissolves when in contact with liquid. Also, through 
immunohistochemistry I attempted to validate the use of MatTek vaginal-
ectocervical models when testing products for vaginal inflammation through a 
comparison of TLR expression in partial and full thickness vaginal-ectocervical 
models and native vaginal and ectocervical tissue.  
MB66 Films and Inflammation 
 Previous studies have shown that topical microbicides using Nonoxynol-9 
have induced inflammation in the vaginal epithelium and increased the risk of 
HIV transmission; therefore, it is vital to ensure that any new topical microbicides 
do not cause the same effect before testing these products in healthy volunteers. 
The MB66 film experiments conducted did not show a significant or great 
increase in inflammation when the MB66 active film was added to the vaginal-
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ectocervical tissue model. There was no significant increase in IL-6 and IL-8 
cytokine expression in the vaginal epithelium when exposed to the MB66 films. 
IL-6 and IL-8 are two major cytokines that play a major role in the inflammatory 
response of the innate immune system; therefore, the lack of increased 
expression when exposed to the microbicidal film indicates that the film did not 
induce inflammation in these tissue models. Since inflammation increases 
susceptibility to HIV infection by potentially exposing leukocytes in the basal layer 
to HIV virions, the lack of IL-6 or IL-8 expression suggests that use of these 
microbicidal films will not increase the risk of HIV infection in initial human safety 
trials. In addition, the cytokine experiment analysis of TNF-alpha showed greater 
expression of TNF-alpha in the apical supernatant of the control as compared to 
the placebo film and the active MB66 film at the same time point. This suggests 
that the addition of the film to the tissue could have quieted the inflammatory 
immune response, leading to less inflammation and TNF-alpha cytokine 
production than the control tissue. More research should be done to determine 
the extent of this effect on vaginal-ectocervical tissue in women. Future research 
should include testing with a larger panel of cytokine analytes or through a safety 
study in health volunteers by testing cervico-vaginal lavages. Finally, when MCP-
1 expression was analyzed results showed that expression of MCP-1 in the basal 
supernatant at the 24 hour time point was significantly greater in both the film 
and the placebo as compared to the control. As MCP-1 is a proinflammatory 
cytokine, formerly known as CCL2, this is an important result to consider. 
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Although this result indicates that both the active MB66 film and the placebo film 
could have induced migratory potential of macrophages and dendritic cells within 
the epithelium of the vaginal-ectocervical tissue, it should be noted that the 
expression of MCP-1 was statistically significant but was not vastly numerically 
different between the three conditions. This could be a statistical artifact. Also, 
there was no significant inflammation indicated in the apical supernatant. The 
MCP-1 expression was increased in detection only in the basal supernatant. 
Since the apical side of the epithelium is the first point of contact with HIV virus, it 
would be more concerning if the inflammation was induced at the host-pathogen 
interface. The basal layer lies underneath the apical layer; therefore, there is still 
some epithelial barrier left between the virus and this slightly inflamed area. 
Although unlikely, additional research should be done to explore the extent of this 
MCP-1 expression in the basal layer lamina propria to ensure that it does not 
increase the risk of HIV infection.  
 In the second cytokine experiment, the MB66 film was placed on vaginal-
ectocervical models grown in the presence of medium and ones grown with  high 
doses of estradiol. Estradiol levels in a female fluctuate throughout the menstrual 
cycle; therefore, it is important to know how the safety of the microbicidal film is 
affected by these hormonal changes, if at all. In addition, studies have suggested 
that high estrogen levels during ovulation could cause the mucosal tract to 
become less viscous and more alkaline, causing increased vulnerability to HIV-1 
infection (Hladik, F., & McElrath, M. J., 2008). Results showed that there was an 
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increase in basal IL-6, IL-8, and TNF-alpha expression in the vaginal-ectocervical 
models grown in the presence of estradiol. Although statistics were not 
completed, as there were singleton or duplicate samples, these results could 
suggest that at certain points during the menstrual cycle when estradiol levels 
are at their greatest, the MB66 microbicidal films could potentially increase 
inflammation slightly in the epithelium and in turn increase risk of HIV infection. 
Although these results may suggest that these topical microbicides films may not 
be a perfect option for HIV prevention, it is important to note that the estradiol 
concentration, 100 nM, is significantly greater than the maximum estradiol 
present in the female human body at any point in the menstrual cycle; therefore, 
these results may not be representative of the actual inflammatory response that 
may occur in native tissue. Another unique result from this experiment was the 
decrease in basal MCP-1 expression when active film was added to the vaginal-
ectovervical model exposed only to medium. This result suggests that in some 
cases, the MB66 microbicidal film could quiet the immune response, as the MCP-
1 expression was decreased when the film was added. Although in the model 
grown only in medium, the difference in MCP-1 expression between the control 
(no film) and MB66 film exposed tissues was not a great difference, it is still a 
trend that should be considered and checked for when completing future 
research with these microbicidal products.  
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TLR Expression in Native Tissue and MatTek Models 
The TLR expression experiment results were performed to validate the 
use of these vaginal-ectocervical models when testing new topical microbicidal 
products. We hypothesized that the native vaginal and ectocervical tissues would 
show similar TLR expression when compared to the partial and full thickness 
vaginal-ectocervical models. Immunohistochemistry results showed a great 
degree of similarity between the native tissue and the models. TLR 2 expression 
was positive in the native tissue as well as the partial and full thickness MatTek 
models. With TLR 3, there was a lack of expression in both the native and the full 
thickness models; in contrast, the basal layer of epithelium of the partial 
thickness MatTek model stained intensely positive for TLR 3. This difference 
between the native and the partial thickness tissue model could indicate that the 
full thickness model better represents the native environment of the lower female 
reproductive tract; therefore, the full thickness vaginal-ectocervical models 
should be used when testing new HIV prevention methods and products. With 
TLR 4, there was positive staining on the majority of the native samples and 
similar expression of TLR 4 was seen in all of the full thickness MatTek models. 
Surprisingly, no specific positive staining for the expression of TLR 4 was seen in 
the partial thickness MatTek models. Similar to the results with TLR 3, these 
results could indicate that the full thickness MatTek models are a better 
representation of the native vaginal-ectocervical environment.  
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 A lack of TLR 5 expression was seen in native tissue as well as both the 
partial and full thickness models. There was no positive staining on the native 
vaginal or ectocervical tissue samples or any of the MatTek models. This result 
shows that the native tissue and the models have similar immune and 
inflammatory responses making both full and partial thickness MatTek models a 
good representation of the native environment. Finally, there was similar staining 
and expression of TLR 9 in all the native tissue samples, as well as the MatTek 
partial and full thickness models. Although there was variability in the staining 
itself and it was not localized to a specific area, as compared to the other TLRs, 
this same type of variable staining was seen in the all of the native and MatTek 
model samples. This result suggests that TLR 9 expression was very comparable 
in the native tissue and in the vaginal-ectocervical tissue models. In addition, 
throughout all of the samples TLR expression, when seen, was concentrated 
mainly in the basal layer. Since the basal layer lies deeper than the less apical 
layer, any inflammation occurring is not present at the host-pathogen interface, 
making the TLR expression here less concerning. Overall, these TLR expression 
results indicate that the MatTek vaginal-ectocervical models provide a valid and 
suitable method for testing out new microbicidal products and can successfully 
replicate the native environment of the lower female reproductive tract.  
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CONCLUSION 
 Even after more than 30 years of research, the scientific community has 
not yet discovered a female-controlled HIV prevention method. As HIV 
prevalence through heterosexual transmission is still quite high in the United 
States and even more so around the world, it is imperative that we continue to 
pursue research and find a discreet and accessible method for women. Topical 
microbicide products, such as the MB66 film, may be the method that could fill 
this void. Through these experiments, the MB66 films were not shown to 
increase inflammation in the vaginal epithelium, suggesting that this product will 
not increase the risk of HIV transmission. Future research should be conducted 
to determine the effectiveness of the MB66 microbicidal film at different points in 
the menstrual cycle to ensure that the fluctuating hormonal levels do not cause 
women to be at increased risk of HIV transmission. Overall, great strides are 
currently being taken in research to find a topical microbicide that can 
successfully curb the spread of HIV, and efforts in this area should continue until 
women around the world are afforded the ability to protect themselves against 
this incurable virus.  
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